Bimeda is pleased to announce that Archie McNeil has joined the company as a full time Equine Sales Representative covering the northeast part of the U.S. Since Bimeda acquired ArthroDynamic in the fall of 2016, Archie had been working with the Bimeda equine group as sales consultant. Archie will continue to call on veterinary clinics and key influencers in the northeast.
Archie has a rich history and legacy in the U.S. equine business. He has worked for companies such as Vetrepharm, Bioniche and Vetoquinol during his 26 years in commercial roles. Prior to working on the commercial side, Archie was an accomplished trainer and rider. Archie has competed in all the major races in the Standard bred industry, such as the Hambletonian, the Little Brown Jug and the Breeders Crown. One of Archie’s major accomplishments was winning the Peter Haughton Memorial at Roosevelt Raceway for $520,000, at that time it, the richest race ever in New York State for either a Thoroughbred or Standard.
McNeil will report directly to Clark Weaver, Equine Sales Manager.
Bimeda Inc, North America
McNeil’s appointment is the latest in a series of significant developments within the Bimeda North America business, and follows on from strategic acquisitions last year within the equine animal health sector. These included the purchase of equine company ArthroDynamic, as well as the acquisition of several prominent equine products from CEVA Animal Health.
With half a century’s experience in the manufacture, distribution and marketing of veterinary pharmaceuticals and animal health products, Bimeda is a well-established global presence in the veterinary pharmaceutical industry.
Since its foundation in Ireland in the mid 1960s, the company’s impressive growth has seen them achieve a truly global footprint; with Bimeda now boasting a presence in over 75 countries, across 6 continents.
Bimeda’s vast product offering covers both livestock and companion animals, and includes products from a broad array of therapeutic classes.
Bimeda’s manufacturing capabilities are enviable, with 10 manufacturing facilities in 7 countries; all operating to the highest regulatory standards. The company manufactures numerous dosage forms, with the capacity for both sterile and non-sterile production.
While Bimeda’s customer-focused culture and an ethos of continuous improvement ensure customers’ current needs and expectations are routinely surpassed, their global R&D programme is committed to anticipating the future needs of the animal health sector. Bimeda’s continued investment in its five state-of-the-art laboratories across four continents is demonstrative of the company’s commitment to serving the future needs of the global animal health market.
Bimeda and its employees remain committed to the company ethos of Global Excellence in Animal Health and to providing animal health professionals and companion animal owners with the products and services which promote optimum animal health and productivity.
For more information on Bimeda, visit www.bimeda.com.